Doug Ingram is a senior executive in the pharmaceutical, medical device and biologics space and currently serves as the CEO and President of Chase Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. Chase Pharmaceuticals will commence its phase 3 registration trail in 2016 for its lead product, CPC-201, which, if successful, promises to be the new standard-of-care in the symptomatic treatment of mild to moderate Alzheimer’s disease.
Prior to this, Doug was the President of Allergan, Inc., responsible for the company’s worldwide commercial performance. In 2014, he led a restructuring and strategic plan enhancement that reduced expenses by $575 million, enhanced sales growth, greatly improved earnings growth, and generated approximately $20 billion in shareholder value on a forward PE basis, while driving in 2014 the best sales and earnings performance in Allergan’s 64-year history. Allergan was acquired by Actavis in 2015 in a transaction valued at approximately $72 billion.
Doug is currently a board member of Pacific Life Insurance Company and board member and Vice Chairman of Nemus Biosciences. He is also a co-founder and board member of the Orange County Marathon. He holds a Bachelor of Science, magna cum laude from Arizona State University and a Doctor of Law (J.D.), summa cum laude and Order of the Coif, from the University of Arizona, James E. Rogers College of Law.